CanCHD Study of Hematopoietic Cancers in Children With and Without Genetic Syndromes

Mohammad Sazzad Hasan1, Elie Ganni2, Aihua Liu2

  • 1Department of Epidemiology, Biostatistics and Occupational Health McGill University Montreal Quebec Canada.

Insights

Children with congenital heart disease (CHD) and genetic syndromes face a significantly higher risk of developing hematopoietic cancer (HC). This study highlights the importance of considering genetic factors in cancer surveillance for these children.

Area of Science:

  • Pediatric Oncology
  • Cardiology
  • Genetics
  • Epidemiology

Background:

  • Congenital heart disease (CHD) and cancer may share common underlying genetic pathways.
  • Reliable risk estimates for hematopoietic cancer (HC) in children with CHD are limited.
  • Genetic syndromes are known to increase susceptibility to various diseases.

Purpose of the Study:

  • To quantify the risk of hematopoietic cancer (HC) in children with congenital heart disease (CHD).
  • To investigate the influence of genetic syndromes on HC risk within this population.
  • To provide data for improved cancer surveillance strategies.

Main Methods:

  • Utilized Canadian CHD and Canadian Cancer Registry (CCR) data (1999-2017).
  • Calculated standardized incidence ratios (SIR) comparing HC incidence in children with CHD to the general pediatric population.
  • Employed Kaplan-Meier curves to estimate cumulative HC incidence with death as a competing risk.

Main Results:

  • A total of 143,794 children with CHD were analyzed.
  • Children with known genetic syndromes had a substantially higher risk of HC (SIR 13.4).
  • Cumulative HC incidence was 2.44% in children with syndromes versus 0.79% without.

Conclusions:

  • Known genetic syndromes are a significant predictor of hematopoietic cancer in children with CHD.
  • This finding is crucial for developing risk-stratified cancer surveillance policies.
  • Early childhood acute myeloid leukemia showed a higher incidence than acute lymphoblastic leukemia.
Abstract

Related Concept Videos

Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K
Overview of Hematopoiesis01:20

Overview of Hematopoiesis

Hematopoiesis, or blood cell production, is a vital biological process that begins early in embryonic development and continues throughout life. This process generates the various types of cells found in blood, including red blood cells, white blood cells, and platelets from hematopoietic stem cells (HSCs).
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...
4.0K
Hematopoiesis01:21

Hematopoiesis

The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
5.3K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
333
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.1K
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
1.4K